特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
200991

ポンペ病:パイプライン製品の分析

Pompe Disease - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 102 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
ポンペ病:パイプライン製品の分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 102 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ポンペ病 (II型糖原病) は遺伝性疾患のひとつで、初発症状としては歩行・呼吸に用いる筋肉が段階的な衰弱が挙げられます。特に幼児が発症した場合は、往々にして心筋に深刻な影響が及びます。αグルコシダーゼ (マルターゼ) というグリコーゲン分解機能のある酵素の突然変異体が、この疾患を引き起こす原因となっています。発症の結果、グリコーゲンが人体 (特に筋肉) に蓄積され、個々の細胞に打撃を与えます。

当レポートでは、世界各国でのポンペ病治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

ポンペ病 - 概要

ポンペ病 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

ポンペ病 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

ポンペ病の治療薬開発に従事している企業

  • Amicus Therapeutics Inc
  • Audentes Therapeutics Inc
  • EpiVax Inc
  • Etubics Corp
  • Genzyme Corp
  • greenovation Biotech GmbH
  • Huons Co Ltd
  • JCR Pharmaceuticals Co Ltd
  • Oxyrane Belgium NV
  • Pharming Group NV
  • Sarepta Therapeutics Inc

薬剤プロファイル

ポンペ病 - 休止中のプロジェクト

ポンペ病 - 開発が中止された製品

ポンペ病 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Pompe Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pompe Disease - Pipeline by Abeona Therapeutics Inc, H1 2020
  • Pompe Disease - Pipeline by Actus Therapeutics Inc, H1 2020
  • Pompe Disease - Pipeline by Amicus Therapeutics Inc, H1 2020
  • Pompe Disease - Pipeline by Audentes Therapeutics Inc, H1 2020
  • Pompe Disease - Pipeline by Avidity Biosciences LLC, H1 2020
  • Pompe Disease - Pipeline by AVROBIO Inc, H1 2020
  • Pompe Disease - Pipeline by EpiVax Inc, H1 2020
  • Pompe Disease - Pipeline by Etubics Corp, H1 2020
  • Pompe Disease - Pipeline by Genzyme Corp, H1 2020
  • Pompe Disease - Pipeline by Greenovation Biotech GmbH, H1 2020
  • Pompe Disease - Pipeline by Icagen Inc, H1 2020
  • Pompe Disease - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2020
  • Pompe Disease - Pipeline by NanoMedSyn SAS, H1 2020
  • Pompe Disease - Pipeline by Oxyrane Belgium NV, H1 2020
  • Pompe Disease - Pipeline by Pharming Group NV, H1 2020
  • Pompe Disease - Pipeline by RespireRx Pharmaceuticals Inc, H1 2020
  • Pompe Disease - Pipeline by Sarepta Therapeutics Inc, H1 2020
  • Pompe Disease - Pipeline by Spark Therapeutics Inc, H1 2020
  • Pompe Disease - Pipeline by Valerion Therapeutics LLC, H1 2020
  • Pompe Disease - Dormant Projects, H1 2020
  • Pompe Disease - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Pompe Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12154IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pompe Disease - Pipeline Review, H1 2020, provides an overview of the Pompe Disease (Metabolic Disorders) pipeline landscape.

Pompe disease is an inherited disorder caused by defect in a gene called GAA. The GAA gene is responsible for the production of the GAA enzyme (acid alpha-glucosidase). This enzyme is needed to break down glycogen, a form of sugar stored in muscle cells. When too much glycogen builds up in the muscle cells, the cells become damaged and the muscles cannot function properly. Symptoms include respiratory failure, muscle pain, proximal muscle weakness, respiratory tract infections, headache and difficulty chewing or jaw muscle fatigue.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pompe Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pompe Disease (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pompe Disease (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pompe Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 1, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Pompe Disease (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pompe Disease (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Pompe Disease (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pompe Disease (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pompe Disease (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pompe Disease (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pompe Disease (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pompe Disease (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Pompe Disease - Overview
  • Pompe Disease - Therapeutics Development
  • Pompe Disease - Therapeutics Assessment
  • Pompe Disease - Companies Involved in Therapeutics Development
  • Pompe Disease - Drug Profiles
  • Pompe Disease - Dormant Projects
  • Pompe Disease - Discontinued Products
  • Pompe Disease - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.